|
|
|
| Short-term clinical efficacy of levothyroxine combined with low-dose creatine phosphate in treatment of heart disease patients with hypothyroidism |
| SU Jia1,YANG Jiong2,ZHANG Xiguo1,LI Liang3 |
| 1. Department of Emergency，3.Fifth Department of Internal Medicine, Inner Mongolian Autonomous Region Corps Hospital ,Chinese People’s Armed Police Forces, Hohhot 010040,China;2. Medical Department，General Hospital of the Chinese People’s Armed Police Forces，Beijing 100039, China |
|
|
|
|
Abstract Objective To study the short-term clinical efficacy of levothyroxine combined with low-dose creatine phosphate in heart disease patients with hypothyroidism. Methods Twenty-six patients were divided into two groups randomly:control group of (n=12) was given levothyroxine for 30 days; observation group (n=13) was given levothyroxine for 30 days combined with low-dose creatine phosphate for 10 days. Before and after 30 days’ treatment,left ventricular end diastolic diameter(LVDd),left ventricular ejection fraction(LVEF),stroke volume(SV) measured by echocardiography were observed.Blood samples were collected to measure the plasma concentrations of creatine kinase(CK),creatine kinase-MB(CK-MB) and lactate dehydrogenase(LDH). Results After 30 days treatment, CK,CK-MB,LDH were significantly decreased in the both groups(P＜0.05),but no difference was found in HR.There were significant differences in CK,CK-MB,LDH between the two groups（P＜0.05 or P＜0.01).In the observation group,there were significant differences in SV,LVEF,LVDd (P＜0.05) after treatment,whereas no difference in the control group and between the two groups. Conclutions Levothyroxine combined with short-term low-dose creatine phosphate may lower myocardial enzymes in serum in heart disease patients with hypothyroidism.
|
|
Received: 20 September 2012
|
|
|
|
|
|
| ［1］ |
Saks V A，Shumia E． Phosphocreatine，molecular and cellular aspacts of the mechanism of cardioprotective action［J］.Curr Ther Res， 1992，53：585-598．［2］ Klein I, Ojamaa K. The thyroid hormone and cardiovascular system［J］.N Eng J Med, 2001，344: 501–509.［3］ Kahaly G J,Dillmann W H.Thyoid hormone action in the heart ［J］.Endocr Rev,2005,26(5):704-728.［4］ Hekimsoy Z, Oktem I K. Serum creatine kinase levels in overt and subclinical hypothyroidism［J］.Endocr Res,2005,31(3):171-175.［5］ 侯立向.一种心肌保护剂：磷酸肌酸［J］.生物化学与生物物理进展2003,30(2):324［6］ 石 佳，袁 素，薛庆华.冠心病患者围手术期应用磷酸肌酸的心肌保护作用研究［J］.中国分子心脏病学杂志，2010,10(1):44-47.(2012-09-20
|
| ［1］ |
Saks V A，Shumia E． Phosphocreatine，molecular and cellular aspacts of the mechanism of cardioprotective action［J］.Curr Ther Res， 1992，53：585-598．［2］ Klein I, Ojamaa K. The thyroid hormone and cardiovascular system［J］.N Eng J Med, 2001，344: 501–509.［3］ Kahaly G J,Dillmann W H.Thyoid hormone action in the heart ［J］.Endocr Rev,2005,26(5):704-728.［4］ Hekimsoy Z, Oktem I K. Serum creatine kinase levels in overt and subclinical hypothyroidism［J］.Endocr Res,2005,31(3):171-175.［5］ 侯立向.一种心肌保护剂：磷酸肌酸［J］.生物化学与生物物理进展2003,30(2):324［6］ 石 佳，袁 素，薛庆华.冠心病患者围手术期应用磷酸肌酸的心肌保护作用研究［J］.中国分子心脏病学杂志，2010,10(1):44-47.(2012-09-20
|
| [1] |
. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(6): 547-548. |
|
|
|
|
2013, Vol. 24 
